<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJOG</journal-id><journal-title-group><journal-title>Open Journal of Obstetrics and Gynecology</journal-title></journal-title-group><issn pub-type="epub">2160-8792</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojog.2015.56047</article-id><article-id pub-id-type="publisher-id">OJOG-57230</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Port-Site Metastasis after Laparoscopic Surgery with Rapid Second Recurrence in Early Stage Endometrial Carcinoma: A Case Report and Review of the Literature
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>oulikha</surname><given-names>Outaggarts</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sarah</surname><given-names>Johnstone</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Annekathryn</surname><given-names>Goodman</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Harvard Medical School, Boston, USA</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>zoulikha.outaggarts@student.uni-tuebingen.de(OO)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>06</month><year>2015</year></pub-date><volume>05</volume><issue>06</issue><fpage>324</fpage><lpage>332</lpage><history><date date-type="received"><day>5</day>	<month>May</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>14</month>	<year>June</year>	</date><date date-type="accepted"><day>17</day>	<month>June</month>	<year>2015</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: Port site metastases have been reported with laparoscopic surgery. The mechanism of action is unknown. Theories include tumor tracking, spillage, pneumoperitoneum, and immune factors. Methods: We report on a case of aggressive port site metastases and intra-abdominal recurrence after an uncomplicated laparoscopic hysterectomy for a grade 2, minimally invasive endometrioid adenocarcinoma of the uterus. The world literature on port site metastases in gynec
  ological cancer is reviewed. 
  Results: Port site metastases have two distinct presentations. In the first 
  pattern, the metastases are isolated to the laparoscopic port sites. In the second pattern, port site metastases are associated with widespread intra-abdominal recurrence. Conclusion: Port site metastases are rare but occur with laparoscopic surgery. Meticulous attention to surgical technique including the use of specimen bags to isolate tissue and prevent spillage should be performed. Data registries should be instituted to track the incidence and outcomes of port site metastases.
 
</p></abstract><kwd-group><kwd>Port Site Metastases</kwd><kwd> Laparoscopic Hysterectomy</kwd><kwd> Endometrial Cancer</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>With the increasing use of laparoscopic surgical techniques to remove the uterus and adnexa in gynecologic cancers, there has been concern that these techniques could alter the natural history of these malignancies by mechanically spreading tumor cells. Tumor implantation in the laparoscopic trocar or port incisions, called “port site metastases” (PSM), has been reported in both multiple case reports and case series. PSM could also occur in the trocar sites which were not used for removing specimens [<xref ref-type="bibr" rid="scirp.57230-ref1">1</xref>] . In a large study with 1694 patients, who underwent laparoscopic surgeries for malignant gynecological cancers, 20 patients (1.18%) developed port-site metastases [<xref ref-type="bibr" rid="scirp.57230-ref2">2</xref>] . Fifteen of them had ovarian or fallopian tube carcinoma and only one patient had uterine cancer [<xref ref-type="bibr" rid="scirp.57230-ref2">2</xref>] . In another report of 295 patients who underwent laparoscopy for endometrial cancer, one patient developed PSM (0.33%) [<xref ref-type="bibr" rid="scirp.57230-ref3">3</xref>] .</p><p>The incidence of port site metastases is frequently associated with other sites of recurrence, and most patients with port site metastases carry a diagnosis of ovarian cancer. In contrast, only eight cases of port-site metastasis along with intra-abdominal recurrence after surgery for endometrial cancer have been reported in literature [<xref ref-type="bibr" rid="scirp.57230-ref4">4</xref>] .</p><p>We describe a patient who developed a rapid recurrence of a minimally invasive, low to intermediate-grade endometrial cancer. The literature on PSM after laparoscopic surgery for malignancies and possible mechanisms of tumor spread in minimally invasive surgery are reviewed.</p></sec><sec id="s2"><title>2. Case Report</title><p>The Patient is a 62-year-old, gravida 2, para 2 woman with BMI of 43.6 kg/m<sup>2</sup>. She was not on hormone replacement therapy. <xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="table" rid="table1">Table 1</xref> summarize her clinical course. She presented with vaginal bleeding.</p><fig-group id="fig1"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Clinical summary.</title></caption><fig id ="fig1_1"><label></label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1430934x6.png"/></fig></fig-group><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Summary of oncologic history</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Date</th><th align="center" valign="middle" >Event</th></tr></thead><tr><td align="center" valign="middle" >1994</td><td align="center" valign="middle" >Treatment of Hodgkin’s Lymphoma by splenectomy, chemotherapy, and radiation.</td></tr><tr><td align="center" valign="middle" >March 2014</td><td align="center" valign="middle" >Development of one year of menometrorrhagia. Biopsy: grade 1 endometrial adenocarcinoma. Cervical cytology: normal. Pelvic ultrasound: 12 &#215; 6.2 &#215; 6.2 cm uterus. Endometrial stripe was 3 cm.</td></tr><tr><td align="center" valign="middle" >April 2014</td><td align="center" valign="middle" >Total laparoscopic hysterectomy, Bilateral salpingo-oophorectomy, lysis of adhesion, release of incarcerated hernia (<xref ref-type="fig" rid="fig5">Figure 5</xref>(a)), omentectomy, cystoscopy and ventral hernia repair. Pathology: Grade 2 endometrioid adenocarcinoma (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref>).</td></tr><tr><td align="center" valign="middle" >May 2014</td><td align="center" valign="middle" >Development of left subclavian and internal jugular deep vein thrombosis. Treated with enoxaparin.</td></tr><tr><td align="center" valign="middle" >June 2014</td><td align="center" valign="middle" >Development of large bowel obstruction. Abdominal CT scan: port site metastases (Figures 5(b)-(d)).</td></tr><tr><td align="center" valign="middle" >July 2014</td><td align="center" valign="middle" >Exploratory laparotomy and complete cytoreductive surgery, resection of port site metastases, sigmoid resection, colostomy Finding: multiple port-site metastasis; omental disease; large tumor mass encasing and penetrating rectum and vagina; plaque of tumor on the external surface of the bladder. No ascites, no peritoneal studding, no carcinomatosis. Pathology: Grade 2 endometrioid adenocarcinoma (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</td></tr><tr><td align="center" valign="middle" >August 2014</td><td align="center" valign="middle" >Admission for pain control and wound infection. Abdominal CT scan: significant regrowth of her disease. Patient received first dose of Carboplatin and Paclitaxel.</td></tr><tr><td align="center" valign="middle" >January 2015</td><td align="center" valign="middle" >Completion of six cycles of Caboplatin and Paclitaxel. Clinical remission: CA-125 marker was 10 U/ml (range 0 - 35) and a negative abdominal CT scan.</td></tr><tr><td align="center" valign="middle" >May 2015</td><td align="center" valign="middle" >No evidence of recurrence.</td></tr></tbody></table></table-wrap><p>An endometrial biopsy revealed a grade 1 endometrial adenocarcinoma. She underwent an uncomplicated laparoscopic hysterectomy with bilateral salpingo-oophorectomy. One month postoperatively, she developed a deep vein thrombosis. She was treated with low molecular weight heparin as anticoagulation therapy. Three months after her hysterectomy, she presented with metastatic tumor in her port sites and a pelvic mass. She underwent an exploration, and fully cytoreductive surgery with excision of the pelvic tumor, upper vaginectomy, sigmoid resection, and end colostomy. One month later, she had evidence of tumor recurrence. Chemotherapy with carboplatin and paclitaxel was started. She received six cycles of chemotherapy with a complete resolution of tumor. She is currently disease-free at five months from completion of chemotherapy.</p>Pathology<p>April 2014: Final pathological diagnosis of April 2014: Endometrioid adenocarcinoma, grade 2 of 3, with limited superficial myometrial invasion to 1 mm and without cervical or vascular invasion. No diagnostic abnormalities were recognized in the ovaries, fallopian tubes and omentum (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>July 2014: Final pathological diagnosis of July 2014: In the skin and abdominal wall, fibrosis with foreign body giant cell reaction, fat necrosis, and mesh were diagnosed. Furthermore metastatic, adenocarcinoma consistent with known endometrial primary were diagnosed in the skin and abdominal wall, multiple abdominal wall</p><fig id="fig2"  position="float"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> Grade 2 endometrioid adenocarcinoma with superficial invasion (10&#215; magnification)</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1430934x7.png"/></fig><fig id="fig3"  position="float"><label><xref ref-type="fig" rid="fig3">Figure 3</xref></label><caption><title> Grade 2 endometrioid adenocarcinma in the uterine specimen (50&#215; magnification)</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1430934x8.png"/></fig><fig id="fig4"  position="float"><label><xref ref-type="fig" rid="fig4">Figure 4</xref></label><caption><title> Abdominal wall portsite metastases</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1430934x9.png"/></fig><p>nodules, omentum, bladder peritoneum and bladder, pelvic lymph nodes, vagina, rectosigmoid colon (extending through muscularis propria; colonic margins negative for tumor). Descending colon had no evidence of malignancy (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p></sec><sec id="s3"><title>3. Discussion</title><p>The mechanism for port-site metastasis (PSM) development is unknown. The reports of PSM have raised the question of whether an environment that promotes tumor dissemination may be created by laparoscopically managed gynecological malignancies. Even for low grade cancers, there is a risk of tumor cell implantation. The main concern is whether port-site metastasis is iatrogenic or is driven by the tumor’s biology, in which the tumor just does not behave as the FIGO criteria would predict. We report a very rare case of port site metastases along with intra-abdominal recurrence in an early stage endometrial cancer (FIGO Stage IA, G2), that developed within a very short time. The first PSM was diagnosed three months after primary laparoscopic surgery and the second PSM-recurrence developed one month after the second surgery which was a laparotomy.</p><sec id="s3_1"><title>3.1. Review of the Literature</title><p>Currently there have been twelve reported cases of PSM after total laparoscopic hysterectomy (TLH). Eight cases had non-isolated PSM and four cases involved isolated PSM, where there was no evidence of an association with peritoneum carcinomatosis [<xref ref-type="bibr" rid="scirp.57230-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref5">5</xref>] . <xref ref-type="table" rid="table2">Table 2</xref> summarizes the characteristics of reported PSM after laparoscopic hysterectomy.</p><p>Although in the present case there was no carcinomatosis, but because of the presence of several intra-abdo- minal metastasis, we consider this case to be a non-isolated port-site metastasis. Two other cases with high- grade carcinoma (IIIA, IIIC) show an even quicker rate of the PSM-development (1 month) [<xref ref-type="bibr" rid="scirp.57230-ref6">6</xref>] , but they had no recurrence of the first PSM. Only one case of the twelve patients had a double PSM, despite an initial low-grade carcinoma (IA, G2) [<xref ref-type="bibr" rid="scirp.57230-ref7">7</xref>] . In comparison to all the other non-isolated cases, our patient had the lowest grade carcinoma and is the only patient who has both a second recurrence and a quick rate of PSM development.</p></sec><sec id="s3_2"><title>3.2. Clinical Significance</title><p>According to the study of Zivanovic et al. where 1694 patients underwent laparoscopic surgeries for malignant gynecological cancers, our patient would have a bad prognosis because of the rapidity of her disease [<xref ref-type="bibr" rid="scirp.57230-ref2">2</xref>] . Their data showed that the only significant predictor of survival was the interval between laparoscopy and detection. Patients who developed port-site metastases within seven months from the laparoscopic surgery had a median survival of twelve months while patients who developed port-site metastasis after seven months had a median survival of 37 months (P = 0.004). This study also demonstrates that of these 1694 patients, 20 (1.18%)</p><fig-group id="fig5"><label><xref ref-type="fig" rid="fig5">Figure 5</xref></label><caption><title> (a) Incarcerated hernia; (b)-(d) CT scan of the abdomen shows metastases in the subcutaneous tissue in the sites of the laparoscopic ports.</title></caption><fig id ="fig5_1"><label>(b)</label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1430934x10.png"/></fig><fig id ="fig5_2"><label>(c)</label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1430934x11.png"/></fig><fig id ="fig5_3"><label>(d)</label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1430934x12.png"/></fig><fig id ="fig5_4"><label></label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1430934x13.png"/></fig></fig-group><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Summary of the published case reports with the present case</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Characteristics</th><th align="center" valign="middle" >Isolated (n = 4) [<xref ref-type="bibr" rid="scirp.57230-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref7">7</xref>] -[<xref ref-type="bibr" rid="scirp.57230-ref9">9</xref>]</th><th align="center" valign="middle" >Non-isolated (n = 8) [<xref ref-type="bibr" rid="scirp.57230-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref9">9</xref>] - [<xref ref-type="bibr" rid="scirp.57230-ref11">11</xref>]</th><th align="center" valign="middle" >Our patient</th></tr></thead><tr><td align="center" valign="middle" >FIGO stage</td><td align="center" valign="middle" >IA, G2-IIB, G2</td><td align="center" valign="middle" >IC, G2-IV</td><td align="center" valign="middle" >IA, G2</td></tr><tr><td align="center" valign="middle" >Onset of disease</td><td align="center" valign="middle" >7 - 48 months</td><td align="center" valign="middle" >1 - 39 months</td><td align="center" valign="middle" >3 months</td></tr><tr><td align="center" valign="middle" >Survival</td><td align="center" valign="middle" >5 - 42 months</td><td align="center" valign="middle" >11 - 53 months</td><td align="center" valign="middle" >Median 12 months</td></tr><tr><td align="center" valign="middle" >Prognosis</td><td align="center" valign="middle" >Poor</td><td align="center" valign="middle" >Poor</td><td align="center" valign="middle" >Poor</td></tr></tbody></table></table-wrap><p>developed port-site metastasis and 95% of those patients (19 patients) had simultaneously port-site metastasis and metastasis to other sites or carcinomatosis. Their conclusion that PSM is a surrogate for advanced disease [<xref ref-type="bibr" rid="scirp.57230-ref2">2</xref>] .</p><p>According to the current data, our patient has three reasons for a poor prognosis. Not only due to her intra-abdonimal metastasis and the occurrence of both PSM in less than 7 months after her TLH, but also due to development of a deep vein thrombosis (DVT) just 1 month after her hysterectomy. DVT is a possible predictor of the presence of an advanced disease in cancer patients [<xref ref-type="bibr" rid="scirp.57230-ref12">12</xref>] . Sorensen et al. concluded that cancer diagnosed in less than one year after an event of venous thromboembolism is associated with an advanced stage of cancer and a poor prognosis [<xref ref-type="bibr" rid="scirp.57230-ref13">13</xref>] .</p><p>In 1978, the first case report of a patient with ovarian carcinoma and ascites who developed PSM two weeks after laparoscopic surgery was reported. Current collective experience has demonstrated that PSM in gynecological malignancies occurs mostly in patients with ovarian cancer and in patients with intraperitoneal dissemination such as ascites or carcinomatosis [<xref ref-type="bibr" rid="scirp.57230-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref14">14</xref>] . An explanation might be that the presence and possible leakage of ascites through the small abdominal incision leads to an increased contamination of these abdominal wall incisions by malignant cells [<xref ref-type="bibr" rid="scirp.57230-ref15">15</xref>] . Also, in other disciplines like in General Surgery and Urological Surgery, a patient with ascites or peritoneal carcinomatosis is considered as the high-risk patient for PSM [<xref ref-type="bibr" rid="scirp.57230-ref16">16</xref>] .</p></sec><sec id="s3_3"><title>3.3. Laparotomy vs Laparoscopy</title><p>There are several benefits of laparoscopic surgery compared to the open approach. These include fewer postoperative complications, reduced risk of morbidity, shorter hospital stays and a quicker recovery which allows the return to normal activities [<xref ref-type="bibr" rid="scirp.57230-ref17">17</xref>] . Also, because of the cosmetic advantage through laparoscopic surgery, more patient satisfaction is achievable.</p><p>While the risk of developing a recurrence in the abdominal wall is greater in small incisions of laparoscopic surgery than in open surgery [<xref ref-type="bibr" rid="scirp.57230-ref6">6</xref>] , there have also been reports of recurrences in the laparotomy incision scar [<xref ref-type="bibr" rid="scirp.57230-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref19">19</xref>] . Interestingly, the disease-free interval from the primary treatment in endometrial cancer patients with laparotomy wound recurrence was a mean of five years [<xref ref-type="bibr" rid="scirp.57230-ref18">18</xref>] compared to the port-site metastasis recurrences in patients undergoing a laparoscopic surgery where there is a mean time to PSM of 15.3 months [<xref ref-type="bibr" rid="scirp.57230-ref4">4</xref>] . In general, the risk of wound metastasis in endometrial cancer patients is not thought to be greater in laparoscopic surgeries compared to open procedures [<xref ref-type="bibr" rid="scirp.57230-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref16">16</xref>] and that in both approaches there are no specific risk factors that could predict metastasis [<xref ref-type="bibr" rid="scirp.57230-ref4">4</xref>] .</p></sec><sec id="s3_4"><title>3.4. Hypothesis of the Mechanism for Port Site Metastases</title><p>There are several hypotheses how PSM can occur. These include: wound contamination, pneumoperitoneum, and immunosuppression due to the carbon dioxide (CO<sub>2</sub>).</p><p>Wound contamination: The extraction of the cancerous specimens through a small port-site incision leads often to a carbon dioxide leakage during the extraction. This can promote free tumor cell movement, which has a high propensity of implantation in the traumatized tissue of the wound [<xref ref-type="bibr" rid="scirp.57230-ref20">20</xref>] . It is also possible that due to the dissection and the extrication of instruments that are contaminated with tumor cells, a wound contamination can occur.</p><p>Pneumoperitoneum: To distend the abdomen and visualize the viscera, CO<sub>2</sub> is used as the insufflation gas during the laparoscopy. It is colorless and rapidly absorbable [<xref ref-type="bibr" rid="scirp.57230-ref21">21</xref>] . Unfortunately the high pneumoperitoneal pressure can stimulate movement of free peritoneal tumor cells, or it may dislocate tumor cells from viscera into the peritoneal cavity [<xref ref-type="bibr" rid="scirp.57230-ref22">22</xref>] . The “chimney effect” occurs due to the pressure gradient of the peritoneum. The gradient leads to an outflow of gas with possible floating tumor cells through the trocar or port site [<xref ref-type="bibr" rid="scirp.57230-ref23">23</xref>] . The “chimney effect” stimulates tumor cell implantation at the port site. The subsequent healing process leads to scar formation with the presence of entrapped tumor cells [<xref ref-type="bibr" rid="scirp.57230-ref24">24</xref>] .</p><p>Immunosuppression: In a mice model and in a human experiment, it had been shown that in the laparoscopy, using carbon dioxide pneumoperitoneum decreased the immune mediators through TNF-alpha inhibition of the peritoneal macrophage (mice model) [<xref ref-type="bibr" rid="scirp.57230-ref25">25</xref>] . This caused a significant decrease in lymphocytes and cytokines during the early postoperative period before returning to normal levels (human experiment) [<xref ref-type="bibr" rid="scirp.57230-ref26">26</xref>] . This transient immunosuppression may promote the migration of tumor cells to the trocar site wound during laparoscopic surgery.</p></sec><sec id="s3_5"><title>3.5. Preventive Measures</title><p>Even though there is no strategy proven to reduce the risk of PSM, there are several preventive measurements suggested. These include routine irrigation of the port sites [<xref ref-type="bibr" rid="scirp.57230-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref28">28</xref>] suturing of the peritoneum and of the fascia [<xref ref-type="bibr" rid="scirp.57230-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref27">27</xref>] , using a protective extraction bag to prevent wound contamination from resected malignant specimens [<xref ref-type="bibr" rid="scirp.57230-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref29">29</xref>] , occlusion of the fallopian tubes with clips or coagulation to prevent the spreading of tumor cell to the peritoneal cavity [<xref ref-type="bibr" rid="scirp.57230-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.57230-ref11">11</xref>] , avoiding manipulation of the uterus [<xref ref-type="bibr" rid="scirp.57230-ref7">7</xref>] , preventing high intra-abdominal pressure to avoid the “chimney effect” and deflating slowly [<xref ref-type="bibr" rid="scirp.57230-ref30">30</xref>] before removing the trocars [<xref ref-type="bibr" rid="scirp.57230-ref3">3</xref>] , systematic resection of port-site scars and initiation of adjuvant therapies with no delay [<xref ref-type="bibr" rid="scirp.57230-ref27">27</xref>] .</p><p>Even in an early low-grade endometrial cancer where these preventive measures were taken, PSM can occur [<xref ref-type="bibr" rid="scirp.57230-ref5">5</xref>] . In our case, some of the previous recommendations were practiced, including using an extraction bag.</p><p>Nevertheless, it was not sufficient to prevent the port-site metastasis. While high-grade histology and advanced stage are risk factors for recurrence, our patient had no surgical or histological risk factors such as high grade, the presence of positive peritoneal cytology, peritoneal studding or carcinomatosis.</p><p>Other currently un-measurable risk factors include tumor biology or genetic predisposition. We suspect that even with surgical attention to the prevention of cell spillage, there will always still be some risk of port-site tumor cell implantation from laparoscopy.</p></sec><sec id="s3_6"><title>3.6. Possible Reasons Why Our Patient Developed Port Site Metastases</title><p>Our patient had a history of Hodgkin’s Lymphoma and the possibility of residual immune suppression from her first malignancy. One hypothesis of why the PSM develops is immune suppression related to pneumoperitoneum, which potentially promotes unrestricted implantation of cancer cells. Another possible reason for the PSM occurrence in this patient might be associated with the surgical complications she has had with her hernia, and the widespread abdominal adhesions. The patient’s severe adhesions were most likely a reaction from her splenectomy (associated with her Hodgkin’s Lymphoma 20 years ago). A two hour-long extensive lysis of adhesions was performed to free up the omentum from the anterior abdominal wall. It is possible that the associated prolonged exposure to CO<sub>2</sub> insufflation, causing the “chimney effect”, stimulated tumor entrapment in the port sites.</p></sec></sec><sec id="s4"><title>4. Conclusion</title><p>The mechanism of PSM where there are no significant risk factors for recurrence is unknown. Several issues are raised by our case but are difficult to answer on the basis of the present published data. The main concern is whether PSM is iatrogenic or influenced by tumor biology and genetic factors. However, the benefits to laparoscopic surgery outweigh the risks as the incidence rate of PSM is low. Prospectively, multi-center data collection about PSM will lead to a better understanding of the risk factors and surgical techniques that increase risk of port-site metastasis.</p></sec><sec id="s5"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.57230-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Tsuyoshi, O., Kuan-Gen, H., Renee, V., Ueng, S.H. and Lee, C.L. (2012) Unusual Trocar Site Metastasis in a Uterine Leiomyosarcoma after Laparoscopic Hysterectomy. Journal of Minimally Invasive Gynecology, 19, 252-254. http://dx.doi.org/10.1016/j.jmig.2011.10.012</mixed-citation></ref><ref id="scirp.57230-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Zivanovic, O., Sonoda, Y., Diaz, J.P., Levine, D.A., Brown, C.L., Chi, D.S., Barakat, R.R. and Abu-Rustum, N.R. (2008) The Rate of Port-Site Metastases after 2251 Laparoscopic Procedures in Women with Underlying Malignant Disease. Gynecologic Oncology, 111, 431-437. http://dx.doi.org/10.1016/j.ygyno.2008.08.024</mixed-citation></ref><ref id="scirp.57230-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Martinez, A., Querleu, D., Leblanc, E., Narducci, F. and Ferron, G. (2010) Low Incidence of Port-Site Metastases after Laparoscopic Staging of Uterine Cancer. Gynecologic Oncology, 118, 145-150. http://dx.doi.org/10.1016/j.ygyno.2010.03.011</mixed-citation></ref><ref id="scirp.57230-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Palomba, S., Falbo, A., Russo, T. and LaSala, G.B. (2012) Port-Site Metastasis after Laparoscopic Surgical Staging of Endometrial Cancer: A Systematic Review of the Published and Unpublished Data. Journal of Minimally Invasive Gynecology, 19, 531-537. http://dx.doi.org/10.1016/j.jmig.2012.03.023</mixed-citation></ref><ref id="scirp.57230-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Palomba, S., Falbo, A., Oppedisano, R., Russo, T. and Zullo, F. (2012) Isolated Port-Site Metastasis after Laparoscopic Surgery for Endometrial Cancer: A Case Report. Gynecologic Oncology Reports, 2, 16-17.http://dx.doi.org/10.1016/j.gynor.2011.11.006</mixed-citation></ref><ref id="scirp.57230-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kadar, N. (1997) Port-Site Recurrences Following Laparoscopic Operations for Gynaecological Malignancies. Obstetrics &amp; Gynecology, 104, 1308-1313. http://dx.doi.org/10.1111/j.1471-0528.1997.tb10980.x</mixed-citation></ref><ref id="scirp.57230-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Muntz, H.G., Goff, B.A., Madsen, B.L. and Yon, J.L. (1999) Port-Site Recurrence after Laparoscopic Surgery for Endometrial Carcinoma. Obstetrics &amp; Gynecology, 93, 807-809. http://dx.doi.org/10.1016/S0029-7844(98)00308-1</mixed-citation></ref><ref id="scirp.57230-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Faught, W. and Fung Kee Fung, M. (1999) Port Site Recurrences Following Laparoscopically Managed Early Stage Endometrial Cancer. International Journal Gynecological Cancer, 9, 256-258. http://dx.doi.org/10.1046/j.1525-1438.1999.09912.x</mixed-citation></ref><ref id="scirp.57230-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Sanjuán, A., Hernández, S., Pahisa, J., Ayuso, J.R., Torné, A., Martínez Román, S., Lejárcegui, J.A., Ordi, J. and Vanrell, J.A. (2005) Port-Site Metastasis after Laparoscopic Surgery for Endometrial Carcinoma: Two Case Reports. Gynecologic Oncology, 96, 539-542. http://dx.doi.org/10.1016/j.ygyno.2004.10.018</mixed-citation></ref><ref id="scirp.57230-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wang, P.H., Yen, M.S., Yuan, C.C., Chao, K.C., Ng, H.T., Lee, W.L. and Chao, H.T. (1997) Port Site Metastasis after Laparoscopic-Assisted Vaginal Hysterectomy for Endometrial Cancer: Possible Mechanisms and Prevention. Gynecologic Oncology, 66, 151-155. http://dx.doi.org/10.1006/gyno.1997.4717</mixed-citation></ref><ref id="scirp.57230-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Maenpaa, J.U., Nyberg, R. and Parkkinen, J. (2009) Port-Site Metastasis Following Laparoscopic Hysterectomy and Bilateral Salpingo-Ophorectomy for Endometrial Carcinoma. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology, 143, 61-62. http://dx.doi.org/10.1016/j.ejogrb.2008.11.002</mixed-citation></ref><ref id="scirp.57230-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Falanga, A. and Zacharski, L. (2005) Deep Vein Thrombosis in Cancer: The Scale of the Problem and Approaches to Management. Annals of Oncology, 16, 696-701. http://dx.doi.org/10.1093/annonc/mdi165</mixed-citation></ref><ref id="scirp.57230-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sorensen, H.T., Mellemkjaer, L., Olsen, J.H. and Baron, J.A. (2000) Prognosis of Cancers Associated with Venous Thromboembolism. The New England Journal of Medicine, 343, 1846-1850. http://dx.doi.org/10.1056/NEJM200012213432504</mixed-citation></ref><ref id="scirp.57230-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Childers, J.M., Aqua, K.A., Surwit, E.A., Hallum, A.V. and Hatch, K.D. (1994) Abdominal-Wall Tumor Implantation after Laparoscopy for Malignant Conditions. Obstetrics &amp; Gynecology, 84, 765-769.</mixed-citation></ref><ref id="scirp.57230-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kruttwagen, R.F.P.M., Swinkels, B.M., Keyser, K.G.G., Doesburg, W.H. and Schijf, C.P.T. (1996) Incidence and Effect on Survival of Abdominal Wall Metastases at Trocar or Puncture Sites Following Laparoscopy or Paracentesis in Women with Ovarian Cancer. Gynecologic Oncology, 60, 233-237. http://dx.doi.org/10.1006/gyno.1996.0031</mixed-citation></ref><ref id="scirp.57230-ref16"><label>16</label><mixed-citation publication-type="book" xlink:type="simple">Chua, T.C., Yan, T.D., Morris, D.L. and Sugarbaker, P.H. (2011) Port-Site Metastasis Following Laparoscopic Surgery. In: Shamsa, A., Ed., Advanced Laparoscopy, Chap. 11, InTech. http://www.intechopen.com/books/advanced-laparoscopy/port-site-metastasis-following-laparoscopic-surgery</mixed-citation></ref><ref id="scirp.57230-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Spirtos, N.M., Schlaerth, J.B., Gross, G.M., Spirtos, T.W., Schlaerth, A.C. and Ballon, S.C. (1996) Cost and Quality-of-Life Analyses of Surgery for Early Endometrial Cancer: Laparotomy versus Laparoscopy. American Journal of Obstetrics &amp; Gynecology, 174, 1795-1800. http://dx.doi.org/10.1016/S0002-9378(96)70212-0</mixed-citation></ref><ref id="scirp.57230-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Macias, V., Baiotto, B., Pardo, J., Munoz, F. and Gabriele, P. (2003) Laparotomy Wound Recurrence of Endometrial Carcinoma. Gynecologic Oncology, 91, 429-434. http://dx.doi.org/10.1016/j.ygyno.2003.07.001</mixed-citation></ref><ref id="scirp.57230-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Balbi, G.C., Cardone, A., Monteverde, A., Passaro, M., Montone, L., Rossiello, R., Visconti, S., Battista, M., Cassese, E. and Landino, I. (2006) Double Laparotomy Wound Recurrence of Endometrial Carcinoma. European Journal of Gynaecological Oncology, 27, 307-309.</mixed-citation></ref><ref id="scirp.57230-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Tseng, L.N., Berends, F.J., Wittich, P.H., Bouvy, N.D., Marquet, R.L., Kazemier, G. and Bonjer, H.J. (1998) Port-Site Metastases: Impact of Local Tissue Trauma and Gas Leakage. Surgical Endoscopy, 12, 1377-1380. http://dx.doi.org/10.1007/s004649900862</mixed-citation></ref><ref id="scirp.57230-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Menes, T. and Spivak, H. (2000) Laparoscopy: Searching for the Proper Insufflation Gas. Surgical Endoscopy, 14, 1050-1056. http://dx.doi.org/10.1007/s004640000216</mixed-citation></ref><ref id="scirp.57230-ref22"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moreira</surname><given-names> H.J.</given-names></name>,<name name-style="western"><surname> Yamaguchi</surname><given-names> T.</given-names></name>,<name name-style="western"><surname> Wexner</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> Singer</surname><given-names> L.</given-names></name>,<name name-style="western"><surname> Zhao</surname><given-names> R.</given-names></name>,<name name-style="western"><surname> Baig</surname><given-names> M.K.</given-names></name>,<name name-style="western"><surname> Mack. J.A.</surname><given-names> Xiong</given-names></name>,<name name-style="western"><surname> H. and Abramson</surname><given-names> S. </given-names></name>,<etal>et al</etal>. (<year>2001</year>)<article-title>Effect of Pneumoperitoneal Pressure on Tumor Dissemination and Tumor Recurrence at Port-Site and Midline Incisions</article-title><source> American Surgeon</source><volume> 67</volume>,<fpage> 369</fpage>-<lpage>373</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.57230-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Hubens, G., Pauwels, M., Hubens, A., Vermeulen, P., Van Marck, P. and Eyskens, E. (1996) The Influence of a Pneumoperitoneum on the Peritoneal Implantation of Free Intraperitoneal Colon Cancer Cells. Surgical Endoscopy, 10, 809-812. http://dx.doi.org/10.1007/BF00189539</mixed-citation></ref><ref id="scirp.57230-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Hirabayashi, Y., Yamaguchi, K., Shiraishi, N., Adachi, Y., Kitamura, H. and Kitano, S. (2002) Development of Port-Site Metastasis after Pneumoperitoneum. Surgical Endoscopy, 16, 864-868. http://dx.doi.org/10.1007/s00464-001-9121-7</mixed-citation></ref><ref id="scirp.57230-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Ost, M.C., Patel, K.P., Rastinehad, A.R., Chu, P.Y., Anderson, A.E., Smith, A.D. and Lee, B.R. (2008) Pneumoperitoneum with Carbon Dioxide Inhibits Macrophage Tumor Necrosis Factor-Alpha Secretion: Source of Transitional-Cell Carcinoma Port-Site Metastasis, with Prophylactic Irrigation Strategies to Decrease Laparoscopic Oncologic Risks. Journal Endourology, 22, 105-112. http://dx.doi.org/10.1089/end.2007.9858</mixed-citation></ref><ref id="scirp.57230-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Evrard, S., Falkenrodt, A., Park, A., Tassetti, V., Mutter, D. and Marescaux, J. (1997) Influence of CO2 Pneumoperitoneum on Systemic and Peritoneal Cell-Mediated Immunity. World Journal Surgery, 21, 353-357. http://dx.doi.org/10.1007/PL00012252</mixed-citation></ref><ref id="scirp.57230-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Ramirez, P.T., Wolf, J.K. and Levenback, C. (2003) Laparoscopic Port-Site Metastases: Etiology and Prevention. Gynecologic Oncology, 91, 179-189. http://dx.doi.org/10.1016/S0090-8258(03)00507-9</mixed-citation></ref><ref id="scirp.57230-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Ndofor, B.T., Soliman, P.T., Schmeler. K.M., Nick, A.M., Frumovitz, M. and Ramirez, P.T. (2011) Rate of Port-Site Metastasis is Uncommon in Patients Undergoing Robotic Surgery for Gynecological Malignancies. International Journal of Gynecological Cancer, 21, 936-940. http://dx.doi.org/10.1097/IGC.0b013e3182174609</mixed-citation></ref><ref id="scirp.57230-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Thomas Jr., C.G. (1961) Tumor Cell Contamination of the Surgical Wound: Experimental and Clinical Observations. Annals Surgery, 153, 697-705. http://dx.doi.org/10.1097/00000658-196105000-00008</mixed-citation></ref><ref id="scirp.57230-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Wang, P.H., Yuan, C.C., Lin, G., Ng, H.T. and Chao, H.T. (1999) Risk Factors Contributing to Early Occurrence of Port Site Metastases of Laparoscopic Surgery for Malignancy. Gynecologic Oncologoy, 72, 38-44. http://dx.doi.org/10.1006/gyno.1998.5128</mixed-citation></ref></ref-list></back></article>